Find a Clinical Trial | Rutgers Cancer Institute of New Jersey

Print this page

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.
Protocol: 042315
Principal Investigator:
Applicable Disease Sites: Breast
A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer
Protocol: 042408
Principal Investigator:
Applicable Disease Sites: Breast
A Multicenter, Open Label, Phase III Extension Trial to Study the Long-Term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Protocol: 051804
Principal Investigator:
Applicable Disease Sites: Any Site
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors.
Protocol: 052008
Principal Investigator:
Applicable Disease Sites: Any Site
A Multicenter, Open-label, Phase 1/1b Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors.
Protocol: 052402
Principal Investigator:
Applicable Disease Sites: Any Site
A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies.
Protocol: 052405
Principal Investigator:
Applicable Disease Sites: Any Site
A Phase Ia/Ib, Open-Label, Multicenter study to evaluate the Safety, Pharmacokinetics, and activity of Ro7759065 as a single agent and in combination with ATEZOLIZUMAB in Patients with locally advanced or metastatic solid tumors
Protocol: 052406
Principal Investigator:
Applicable Disease Sites: Any Site
A Phase II Trial of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma.
Protocol: 072105
Principal Investigator:
Applicable Disease Sites: Liver
Pilot Study to Investigate Targetable Metabolic Pathways Sustaining Pancreatic Cancer and Associated Genomic Alterations.
Protocol: 072107
Principal Investigator:
Applicable Disease Sites: Pancreas
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207
Principal Investigator:
Applicable Disease Sites: Colon
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition.
Protocol: 082304
Principal Investigator:
Applicable Disease Sites: Prostate
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer.
Protocol: 082305
Principal Investigator:
Applicable Disease Sites: Kidney
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment.
Protocol: 082403
Principal Investigator:
Applicable Disease Sites: Urinary Bladder
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO).
Protocol: 092305
Principal Investigator:
Applicable Disease Sites: Melanoma, Skin
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status.
Protocol: 102302
Principal Investigator:
Applicable Disease Sites: Other Female Genital
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers.
Protocol: 102402
Principal Investigator:
Applicable Disease Sites: Ovary